Avalyn Pharma (NASDAQ:AVLN) Issues Earnings Results

Avalyn Pharma (NASDAQ:AVLN) posted its earnings results on Wednesday. The company reported ($21.83) EPS for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45), Zacks reports.

Avalyn Pharma Price Performance

AVLN opened at $27.09 on Friday. Avalyn Pharma has a fifty-two week low of $24.15 and a fifty-two week high of $32.22.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on AVLN shares. Evercore started coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 target price for the company. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $52.00 target price for the company. Guggenheim started coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $80.00 target price for the company. Finally, Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $59.00.

Insiders Place Their Bets

In other news, Director Jill Carroll bought 277,778 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were bought at an average price of $18.00 per share, for a total transaction of $5,000,004.00. Following the purchase, the director owned 2,186,562 shares in the company, valued at $39,358,116. This represents a 14.55% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were purchased at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the purchase, the insider owned 2,186,562 shares in the company, valued at $39,358,116. This represents a 34.06% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.